- Home
- IMNN vs SNTI Comparison
IMNN vs SNTI Comparison
Compare IMNN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- SNTI
- Stock Information
- Founded
- IMNN 1982
- SNTI 2016
- Country
- IMNN United States
- SNTI United States
- Employees
- IMNN N/A
- SNTI N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- SNTI Health Care
- Exchange
- IMNN Nasdaq
- SNTI Nasdaq
- Market Cap
- IMNN 12.1M
- SNTI 85.3M
- IPO Year
- IMNN 1985
- SNTI N/A
- Fundamental
- Price
- IMNN $0.79
- SNTI $2.11
- Analyst Decision
- IMNN Buy
- SNTI Strong Buy
- Analyst Count
- IMNN 2
- SNTI 2
- Target Price
- IMNN $14.00
- SNTI $8.50
- AVG Volume (30 Days)
- IMNN 3.9M
- SNTI 369.7K
- Earning Date
- IMNN 08-13-2025
- SNTI 08-12-2025
- Dividend Yield
- IMNN N/A
- SNTI N/A
- EPS Growth
- IMNN N/A
- SNTI N/A
- EPS
- IMNN N/A
- SNTI N/A
- Revenue
- IMNN N/A
- SNTI N/A
- Revenue This Year
- IMNN N/A
- SNTI N/A
- Revenue Next Year
- IMNN N/A
- SNTI $150.00
- P/E Ratio
- IMNN N/A
- SNTI N/A
- Revenue Growth
- IMNN N/A
- SNTI N/A
- 52 Week Low
- IMNN $0.37
- SNTI $1.52
- 52 Week High
- IMNN $3.65
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- IMNN 40.14
- SNTI 34.04
- Support Level
- IMNN $0.93
- SNTI $1.90
- Resistance Level
- IMNN $1.03
- SNTI $3.40
- Average True Range (ATR)
- IMNN 0.18
- SNTI 0.42
- MACD
- IMNN -0.10
- SNTI -0.09
- Stochastic Oscillator
- IMNN 1.39
- SNTI 10.58
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.